These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22246377)

  • 1. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.
    Nathanson D; Ullman B; Löfström U; Hedman A; Frick M; Sjöholm A; Nyström T
    Diabetologia; 2012 Apr; 55(4):926-35. PubMed ID: 22246377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Diabetes Res Clin Pract; 2017 Feb; 124():1-10. PubMed ID: 28086201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
    Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Horowitz M; Jones KL; Rayner CK
    Diab Vasc Dis Res; 2017 Jan; 14(1):59-63. PubMed ID: 27941058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.
    Scalzo RL; Moreau KL; Ozemek C; Herlache L; McMillin S; Gilligan S; Huebschmann AG; Bauer TA; Dorosz J; Reusch JE; Regensteiner JG
    J Diabetes Complications; 2017 Feb; 31(2):449-455. PubMed ID: 27884660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.
    Halbirk M; Nørrelund H; Møller N; Holst JJ; Schmitz O; Nielsen R; Nielsen-Kudsk JE; Nielsen SS; Nielsen TT; Eiskjaer H; Bøtker HE; Wiggers H
    Am J Physiol Heart Circ Physiol; 2010 Mar; 298(3):H1096-102. PubMed ID: 20081109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.
    Gill A; Hoogwerf BJ; Burger J; Bruce S; Macconell L; Yan P; Braun D; Giaconia J; Malone J
    Cardiovasc Diabetol; 2010 Jan; 9():6. PubMed ID: 20109208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
    Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
    Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of incretin-based therapy in patients with heart failure and myocardial infarction.
    Mikhail N
    Endocrine; 2014 Sep; 47(1):21-8. PubMed ID: 24493030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
    Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure.
    Nathanson D; Frick M; Ullman B; Nyström T
    Diabetol Metab Syndr; 2016; 8():5. PubMed ID: 26759609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.
    Lipš M; Mráz M; Kloučková J; Kopecký P; Dobiáš M; Křížová J; Lindner J; Diamant M; Haluzík M
    Diabetes Obes Metab; 2017 Dec; 19(12):1818-1822. PubMed ID: 28581209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes.
    Kadowaki T; Namba M; Yamamura A; Sowa H; Wolka AM; Brodows RG
    Endocr J; 2009; 56(3):415-24. PubMed ID: 19194050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.